MaMiDaPP: Mindfulness to Reduce Post-cesarean Pain and Prevent Postpartum Depression

Sponsor
University of Illinois at Urbana-Champaign (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05400382
Collaborator
University of Pittsburgh Medical Center (Other), Southern Illinois University (Other), Arrowhead Regional Medical Center (Other), Feinberg School of Medicine, Northwestern University (Other)
75
2
33

Study Details

Study Description

Brief Summary

This study will test the effect of a mobile mindfulness-based intervention on reducing post-cesarean delivery pain and preventing postpartum depression.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Mindfulness
N/A

Detailed Description

This clinical trial will test the effect of a mobile mindfulness-based intervention on reducing post-cesarean delivery pain and preventing postpartum depression.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
75 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Optimizing Mindfulness to Reduce Post-cesarean Pain and Prevent Postpartum Depression
Anticipated Study Start Date :
Jul 1, 2023
Anticipated Primary Completion Date :
Mar 31, 2026
Anticipated Study Completion Date :
Mar 31, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Mindfulness

Receiving mobile, self-guided mindfulness intervention

Behavioral: Mindfulness
Meditation training to help reduce stress and reactivity to pain and other stressors.
Other Names:
  • Mindfulness meditation
  • No Intervention: Treatment as usual with monitoring

    Receiving treatment as usual with monitoring by study PI and investigators.

    Outcome Measures

    Primary Outcome Measures

    1. Postpartum depression [4 weeks - 6 months]

      depressive symptoms EPDS 13 or higher

    Secondary Outcome Measures

    1. Post-operative pain [4 weeks - 6 months]

      Post-cesarean delivery pain

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • 18-45 years of age, have a singleton pregnancy, score less than 10 on the Edinburgh Postnatal Depression Scale (EPDS; (Cox et al., 1987b), willing to participate in the eight-week intervention or be randomized to the TAUM condition, have no significant psychiatric disorders other than depression or anxiety (e.g., bipolar disorder, substance use disorder, etc.), have no chronic pain condition (e.g., fibromyalgia), and proficient in English or Spanish
    Exclusion Criteria:
    • Women who screen 10 or higher on the EPDS

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • University of Illinois at Urbana-Champaign
    • University of Pittsburgh Medical Center
    • Southern Illinois University
    • Arrowhead Regional Medical Center
    • Feinberg School of Medicine, Northwestern University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Sandraluz Lara-Cinisomo, Associate Professor, University of Illinois at Urbana-Champaign
    ClinicalTrials.gov Identifier:
    NCT05400382
    Other Study ID Numbers:
    • MaMiDaPP
    First Posted:
    Jun 1, 2022
    Last Update Posted:
    Jun 1, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Sandraluz Lara-Cinisomo, Associate Professor, University of Illinois at Urbana-Champaign
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 1, 2022